OBJECTIVES: The objective of this study was to determine, from the perspective of PMH, the financial impact of treating patients with CLL using R and intravenous FC (R-FC IV) versus R and orally administered FC (R-FC PO). METHODS: A cost analysis was performed from the perspective of PMH. All drug and administration costs were obtained from relevant sources in the province of Ontario and validated by PMH. Rituximab dosing was set at 375 mg/m2 for cycle 1 (day 1) and 500 mg/m2 of cycles 2-6 (day 1). Intravenous F and C were dosed at 25 mg/m2 and 250 mg/m2, respectively, for 6 cycles (days 1-3). Oral dosing of these drugs was set at 40 mg/m2 and 325 mg/m2, respectively. Drug utilization was estimated based on a body surface area of 1.8 m2. RESULTS: The cost of R-FC PO at PMH is $32,634 per patient (Drug cost: $29,292; Administration cost: $3,342), while the cost of R-FC IV is $33,400 per patient (Drug cost: $25,192; Administration cost: $8,208). Overall, utilization of R-FC PO is $766, or 2%, less costly than R-FC IV at PMH. Real-world conditions would impact the difference in price between these two options, as patients may tolerate more treatment cycles of one regimen compared to another. The cost of the PO and IV routes of administration may be viewed as functionally equivalent at PMH, making the decision to employ a specific route of administration one that should be based on non-financial criteria. These results should apply to all Canadian hospitals with drug and administration costs that are similar to those found at PMH. CONCLUSIONS: This analysis shows that R-FC PO is marginally less expensive than R-FC IV at PMH. Therefore, the choice of format should be made based on patients’ individual needs.